세계의 축성 척추관절염(AXSPA) 시장

Global Axial Spondyloarthritis (AXSPA) Market to Reach US$8.4 Billion by 2030

The global market for Axial Spondyloarthritis (AXSPA) estimated at US$6.4 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Ankylosing Spondylitis, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Non-Radiographic Axial Spondyloarthritis segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 7.2% CAGR

The Axial Spondyloarthritis (AXSPA) market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Axial Spondyloarthritis (AxSpA) Market - Key Trends & Drivers Summarized

Why Is Axial Spondyloarthritis Gaining Visibility as a High-Burden Chronic Condition Requiring Early Diagnosis and Long-Term Therapeutic Management?

Axial spondyloarthritis (AxSpA) is drawing increased clinical and commercial focus as its prevalence and long-term impact on patient quality of life become more widely recognized. This inflammatory rheumatic disease primarily affects the spine and sacroiliac joints, manifesting as chronic back pain, stiffness, and reduced mobility. Despite its disabling nature, AxSpA remains underdiagnosed or misdiagnosed for years due to symptom overlap with non-inflammatory back pain and lack of early imaging-based confirmation.

The disease encompasses two subsets-radiographic AxSpA (ankylosing spondylitis) and non-radiographic AxSpA-both of which can progress toward spinal fusion and irreversible joint damage if not adequately managed. The burden on working-age adults is particularly significant, with functional impairment, fatigue, and associated comorbidities such as uveitis, psoriasis, and inflammatory bowel disease further compounding healthcare complexity. These factors underscore the need for early, accurate diagnosis and sustained access to disease-modifying therapies.

Growing awareness campaigns, improvements in MRI-based diagnostic protocols, and revised clinical guidelines from rheumatology societies are helping increase recognition of AxSpA across healthcare systems. As more patients are identified earlier in their disease journey, demand for effective long-term therapeutic solutions is rising. Payers and healthcare providers are increasingly treating AxSpA as a priority chronic condition requiring integrated care models, long-term monitoring, and outcome-driven therapy optimization.

How Are Biologic Therapies, Precision Diagnostics, and Treatment Guidelines Advancing Patient Outcomes in AxSpA?

Biologic therapies-particularly tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors-have become the cornerstone of AxSpA treatment for patients who do not respond adequately to NSAIDs. These agents not only reduce inflammation and alleviate symptoms but also help slow structural damage progression. IL-17 inhibitors, such as secukinumab and ixekizumab, are gaining traction due to their efficacy in both radiographic and non-radiographic forms of AxSpA, providing a targeted alternative for TNF-inadequate responders.

Precision diagnostics are advancing treatment decisions, with HLA-B27 genetic testing, MRI-based inflammation assessment, and biomarker profiling enabling earlier diagnosis and stratified care. As understanding of disease heterogeneity improves, rheumatologists are increasingly leveraging these tools to differentiate AxSpA from mechanical back pain and tailor treatment pathways. The ability to confirm diagnosis prior to visible radiographic changes is critical in initiating timely intervention and avoiding irreversible joint damage.

Updated treatment guidelines from entities such as ASAS, EULAR, and ACR are standardizing care approaches and encouraging early referral to specialists. Stepwise escalation protocols-starting with NSAIDs, moving to biologics upon inadequate response, and integrating physiotherapy and lifestyle modifications-are guiding clinical decision-making. These frameworks are helping align payer policies, reduce delays in access to advanced therapies, and improve long-term disease control in diverse healthcare settings.

Which Patient Demographics, Regional Dynamics, and Access Models Are Driving Therapeutic Demand in the AxSpA Market?

AxSpA primarily affects individuals in their 20s to 40s, a demographic that underscores its societal and economic impact due to reduced workforce participation, absenteeism, and long-term disability. Gender-related differences in presentation and disease progression are influencing diagnosis and treatment patterns, as women with non-radiographic AxSpA often present with atypical symptoms and face delayed diagnosis. This has catalyzed efforts to improve gender-sensitive screening and raise clinical suspicion among primary care providers.

Regionally, Europe and North America lead in diagnosis and treatment adoption, supported by specialist density, advanced diagnostic infrastructure, and broad access to biologics through public and private insurance systems. Asia-Pacific markets, particularly Japan and South Korea, are seeing increased diagnosis rates due to awareness campaigns and investment in rheumatology capacity. Emerging markets, while lagging in biologic accessibility, are expanding non-biologic treatment volumes and initiating government-funded pilot programs to enhance early detection and subsidized care.

Access models are evolving to address cost barriers associated with biologic treatment. Biosimilars are expanding therapeutic options at lower price points, enabling broader patient coverage and inclusion in national reimbursement schemes. Value-based pricing frameworks and risk-sharing agreements are being explored to align therapy costs with real-world outcomes. Meanwhile, patient assistance programs and digital health support tools are improving treatment adherence and enabling continuous disease monitoring in remote or underserved populations.

How Are Drug Development Pipelines, Digital Monitoring Tools, and Multimodal Care Models Shaping the Market Outlook?

The drug development pipeline for AxSpA is diversifying beyond TNF and IL-17 pathways, with investigational therapies targeting JAK-STAT signaling, GM-CSF inhibition, and novel cytokine pathways. Oral small molecules, in particular, are drawing attention for their ease of administration and potential to expand treatment to earlier stages or biologic-naive populations. Clinical trials are increasingly stratifying by disease subtype, HLA-B27 status, and prior biologic exposure to better understand differential responses and optimize treatment sequencing.

Digital tools for symptom tracking, treatment adherence, and disease activity monitoring are enhancing patient engagement and enabling data-driven care models. Mobile apps, wearables, and AI-based decision support systems are being integrated into rheumatology workflows to track pain, stiffness, sleep disruption, and mobility over time. These platforms are supporting remote consultations, treatment adjustments, and early identification of disease flares-improving real-time management and long-term outcome tracking.

Multimodal care models that combine pharmacological treatment with physiotherapy, psychological support, and lifestyle interventions are gaining traction in both public and private healthcare systems. As the chronic and multifaceted nature of AxSpA becomes more apparent, care coordination between rheumatologists, physiatrists, psychologists, and primary care providers is being emphasized. These integrated models not only improve patient-reported outcomes but also reduce healthcare utilization and overall cost of care.

What Are the Factors Driving Growth in the Axial Spondyloarthritis (AxSpA) Market?

The AxSpA market is expanding as diagnostic precision, biologic innovation, and healthcare system awareness converge to reframe the condition as a manageable chronic disease with tangible long-term benefits from early and sustained treatment. The shift from underdiagnosis to proactive disease monitoring is enabling better patient stratification and therapy alignment.

Key growth drivers include rising prevalence among working-age populations, expanding access to biologics and biosimilars, global guideline harmonization, and increasing payer willingness to reimburse early-stage intervention. The integration of digital health tools and coordinated care models is further reinforcing market maturity and patient-centric innovation.

As chronic inflammatory diseases move to the forefront of healthcare priorities, could axial spondyloarthritis become a model for how early detection, precision therapy, and integrated care redefine long-term outcomes in autoimmune disease management?

SCOPE OF STUDY:

The report analyzes the Axial Spondyloarthritis (AXSPA) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Deutschland GmbH & Co. KG
• AbbVie Inc.
• Acelyrin, Inc.
• Affibody AB
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Galapagos NV
• Gilead Sciences, Inc.
• GlaxoSmithKline plc (GSK)
• Inmagene Biopharmaceuticals
• Janssen Biotech, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Axial Spondyloarthritis (AXSPA) - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Awareness and Diagnostic Advancements Throw the Spotlight on Axial Spondyloarthritis Management
  • Growth in Biologic and Targeted Synthetic DMARD Pipelines Spurs Development of Disease-Modifying Treatments
  • Expansion of Diagnostic Imaging Access Improves Early Detection and Reduces Diagnostic Delays
  • Adoption of Multidisciplinary Treatment Models Supports Integrated Care Across Rheumatology and Rehabilitation
  • Increased Focus on Patient-Reported Outcome Measures Enhances Personalized Treatment Planning
  • Use of AI in Image Interpretation and Disease Progression Tracking Supports Clinical Decision-Making
  • Growth in Patient Advocacy and Education Drives Demand for Timely Diagnosis and Access to Therapy
  • Global Guidelines Supporting Early Biologic Intervention Create Opportunities for Market Expansion
  • OEMs Developing Oral Small Molecules for AXSPA Address Adherence Challenges in Injectable Therapies
  • Digital Health Tools and Telemedicine Platforms Improve Disease Monitoring and Treatment Compliance
  • Rising Prevalence of AXSPA Among Younger Adults Fuels Long-Term Market Potential for Chronic Management
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Axial Spondyloarthritis (AXSPA) Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Non-Radiographic Axial Spondyloarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Non-Radiographic Axial Spondyloarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Non-Radiographic Axial Spondyloarthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: USA 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: Canada 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• JAPAN
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: Japan 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• CHINA
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: China 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• EUROPE
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: Europe 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: Europe 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• FRANCE
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: France 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• GERMANY
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Germany 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Italy 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: UK 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 41: Spain Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Spain Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Spain 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 44: Russia Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Russia Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Russia 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Rest of Europe Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Rest of Europe 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Asia-Pacific Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Asia-Pacific 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Asia-Pacific Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Asia-Pacific 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 56: Australia Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Australia Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Australia 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• INDIA
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 59: India Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: India Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: India 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 62: South Korea Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: South Korea Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: South Korea 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Rest of Asia-Pacific Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 68: Latin America Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Latin America Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Latin America 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 71: Latin America Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Latin America Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Latin America 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 74: Argentina Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Argentina Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Argentina 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 77: Brazil Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Brazil Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Brazil 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 80: Mexico Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Mexico Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Mexico 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Rest of Latin America Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Rest of Latin America 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 86: Middle East Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Middle East Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Middle East 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 89: Middle East Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Middle East Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Middle East 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 92: Iran Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Iran Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Iran 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 95: Israel Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Israel Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Israel 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Saudi Arabia Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Saudi Arabia 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 101: UAE Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UAE Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: UAE 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Middle East Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of Middle East 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
• AFRICA
  • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 107: Africa Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Africa Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Africa 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030

IV. COMPETITION